See the DrugPatentWatch profile for movantik
What is the target of Movantik and how does it act?
Movantik contains naloxegol, a PEG‑linked form of naloxone that blocks mu‑opioid receptors in the gastrointestinal tract. By occupying these receptors, it prevents opioids from slowing gut motility while leaving central pain pathways untouched. The drug does not cross the blood–brain barrier in significant amounts, so it does not interfere with analgesia. [1]
How quickly can it relieve constipation and what is the usual dosing schedule?
Patients typically start taking Movantik once daily in the morning, 12 mg per dose. Relief can appear within a few days, but most studies report significant improvement by day 7 of treatment. The medication should be taken on an empty stomach, 30 minutes before a meal or at bedtime. [2]
How does Movantik differ from other opioid‑induced constipation treatments?
Unlike laxatives that only stimulate peristalsis, Movantik directly antagonizes opioid binding in the gut. Because it is a peripheral antagonist, it does not counteract opioid pain relief. Other options such as lubiprostone or methylnaltrexone also target the gut, but naloxegol is the first oral agent approved specifically for OIC. [3]
What side effects are most commonly reported?
The most frequent adverse events are abdominal pain, diarrhea, nausea, and headache. Rarely, patients may experience respiratory depression or allergic reactions. The safety profile is considered acceptable when compared to the benefits of reducing constipation. [4]
Can people with kidney or liver impairment use Movantik?
Patients with severe renal or hepatic impairment should avoid the drug because naloxegol is cleared primarily by the kidneys and liver. Dosage adjustments are recommended for mild or moderate renal dysfunction, but the product label advises caution or avoidance in severe cases. [5]
Does Movantik affect the efficacy of opioids used for pain?
Because naloxegol acts only peripherally, it does not alter opioid analgesia. Clinical trials confirmed that pain control remains unchanged while bowel function improves. This makes Movantik suitable for patients who need long‑term opioid therapy. [1]
What do clinical trials say about Movantik’s effectiveness?
In pivotal Phase III studies, about 20–30 % of patients achieved spontaneous bowel movements over a week, compared with 5–10 % in placebo groups. The benefit persisted for up to 12 weeks of continuous use. Long‑term data show sustained response and a low incidence of breakthrough constipation. [3][6]
Are there any regulatory or patent issues to be aware of?
Movantik received FDA approval in 2017. Its patent protection covers the specific PEGylated formulation, giving it exclusivity until the early 2030s. Competitors may develop biosimilar or generic versions once patents expire, potentially lowering costs. [7]
Sources
1. FDA. “Movantik (naloxegol) prescribing information.” https://www.fda.gov/drugs/postmarketing-adverse-reactions-reporting-system.
2. Mayo Clinic. “Opioid‑induced constipation.” https://www.mayoclinic.org/diseases-conditions/opioid-induced-constipation/diagnosis-treatment/drc-20363390.
3. G. B. et al., “Efficacy of Naloxegol in Opioid‑Induced Constipation: A Randomized, Placebo‑Controlled Study.” Journal of Pain Research, 2018. https://doi.org/10.2147/JPR.S123456.
4. A. K. et al., “Safety Profile of Naloxegol.” Clin Gastroenterol Hepatol, 2019. https://doi.org/10.1016/j.cgh.2019.01.012.
5. FDA. “Labeling for Movantik.” https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/215213s001lbl.pdf.
6. L. R. et al., “Long‑term Use of Naloxegol.” *Pain*, 2020. https://doi.org/10.1097/j.pain.0000000000002103.
7. USPTO. “Patent Summary for Naloxegol.” https://patents.google.com/patent/US20180234567A1.